Merck’s ‘COVID Pill’ Shows Promise, But Mortality Benefits Will Be Hard To Prove
Accurate Viral Test Shows Drug’s Promise
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
You may also be interested in...
In this week's podcast version of Five Must-Know Things, hear about Roche's deal-making in a pandemic, coronavirus vaccine disinformation, Amgen’s Five Prime acquisition, a Novartis clinical trial failure, and new data for a Merck antiviral for the coronavirus.
Swiss biotech Molecular Partners will receive upfront payment of CHF60m, including equity.
The UK biotech aims to raise $100m, but will need to tackle safety concerns to secure a long-term future.